MEFOPA
European Project on Mendelian Forms of Parkinson’s Disease
| Coordinatore | EBERHARD KARLS UNIVERSITAET TUEBINGEN
Organization address
address: GESCHWISTER-SCHOLL-PLATZ contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Sito del progetto | http://www.mefopa.eu |
| Totale costo | 8˙053˙959 € |
| EC contributo | 5˙759˙468 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2009-single-stage |
| Funding Scheme | CP-FP |
| Anno di inizio | 2010 |
| Periodo (anno-mese-giorno) | 2010-04-01 - 2013-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Organization address
address: GESCHWISTER-SCHOLL-PLATZ contact info |
DE (TUEBINGEN) | coordinator | 1˙761˙498.00 |
| 2 |
STICHTING VU-VUMC
Organization address
address: DE BOELELAAN 1105 contact info |
NL (AMSTERDAM) | participant | 519˙000.00 |
| 3 |
TROPHOS SA
Organization address
address: PARC SCIENTIFIQUE LUMINY CASE 931 contact info |
FR (MARSEILLE CEDEX 9) | participant | 362˙364.00 |
| 4 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
Organization address
address: The Old Schools, Trinity Lane contact info |
UK (CAMBRIDGE) | participant | 360˙000.00 |
| 5 |
LUNDS UNIVERSITET
Organization address
address: Paradisgatan 5c contact info |
SE (LUND) | participant | 352˙800.00 |
| 6 |
KATHOLIEKE UNIVERSITEIT LEUVEN
Organization address
address: Oude Markt 13 contact info |
BE (LEUVEN) | participant | 330˙000.00 |
| 7 |
AARHUS UNIVERSITET
Organization address
address: Nordre Ringgade 1 contact info |
DK (AARHUS C) | participant | 324˙000.00 |
| 8 |
THE UNIVERSITY OF SHEFFIELD
Organization address
address: FIRTH COURT WESTERN BANK contact info |
UK (SHEFFIELD) | participant | 288˙316.00 |
| 9 |
NOVARTIS PHARMA AG
Organization address
address: LICHTSTRASSE 35 contact info |
CH (BASEL) | participant | 288˙000.00 |
| 10 |
INSTITUTO DE MEDICINA MOLECULAR
Organization address
address: AVENIDA PROF EGAS MONIZ contact info |
PT (LISBOA) | participant | 285˙090.00 |
| 11 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 268˙800.00 |
| 12 |
"BIOMEDICAL RESEARCH FOUNDATION, ACADEMY OF ATHENS"
Organization address
address: Soranou Efesiou 4 contact info |
EL (ATHENS) | participant | 216˙000.00 |
| 13 |
UNIVERSITAET ZU LUEBECK
Organization address
address: RATZEBURGER ALLEE 160 contact info |
DE (LUEBECK) | participant | 114˙000.00 |
| 14 |
FONDAZIONE CASA SOLLIEVO DELLA SOFFERENZA
Organization address
address: VIALE CAPPUCCINI SC contact info |
IT (SAN GIOVANNI ROTONDO FG) | participant | 97˙800.00 |
| 15 |
NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS
Organization address
address: CHRISTOU LADA 6 contact info |
EL (ATHENS) | participant | 49˙800.00 |
| 16 |
FUNDACIO PRIVADA CLINIC PER A LA RECERCA BIOMEDICA
Organization address
address: CARRER ROSSELLO 149-153 contact info |
ES (BARCELONA) | participant | 42˙000.00 |
| 17 |
FUNDACION DE ESTUDIOS NEUROLOGICOS ILUNDAIN
Organization address
address: PASEO DE FRANCIA 12 contact info |
ES (SAN SEBASTIAN) | participant | 42˙000.00 |
| 18 |
OSLO UNIVERSITETSSYKEHUS HF
Organization address
address: FORSKNINGSVEIEN 2B contact info |
NO (OSLO) | participant | 30˙600.00 |
| 19 |
ISTANBUL UNIVERSITESI
Organization address
address: ISTANBUL UNIVERSITESI CENTER CAMPUS BEYAZIT EMINONU contact info |
TR (ISTANBUL) | participant | 25˙000.00 |
| 20 |
SEMMELWEIS EGYETEM
Organization address
address: Ulloi ut 26 contact info |
HU (BUDAPEST) | participant | 2˙400.00 |
| 21 |
UNITED ARAB EMIRATES UNIVERSITY
Organization address
address: United Arab Emirates University contact info |
AE (AL AIN) | participant | 0.00 |
| 22 |
UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
UK (LONDON) | participant | 0.00 |
| 23 |
VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG
Organization address
address: De Boelelaan 1105 contact info |
NL (AMSTERDAM) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The Collaborative Project on Mendelian Forms of Parkinson’s Disease (MEFOPA) will bring together the major groups in Europe with a track-record in basic and clinical research on rare Mendelian forms of Parkinson’s disease (PD) in order to identify and validate relevant disease-related molecular pathways, drug-targets and biomarkers for disease susceptibility and progression.. Over the last years it has become increasingly clear that progress in the understanding of the molecular basis of PD, the second most common neurodegenerative disorder, and hence the chance to develop effective disease-modifying treatments, will most likely be brought about by focusing on the rare variants of the disease with known genetic defects. The groups forming the MEFOPA-consortium will therefore analyze the molecular pathways underlying inherited forms of PD with autosomal-dominant and autosomal-recessive inheritance in an integrative way, using cellular and animal models and cutting-edge technology. These two subprojects will provide targets for novel, disease-modifying treatment strategies. In a third subproject, a European registry and biobank for patients with rare Mendelian forms of PD will be established. Body fluids will be collected and systematically analyzed by unbiased proteomic techniques as well as by focussed analysis of candidate proteins, and ex vivo cellular models will be generated, in order to allow validation of disease-related alterations detected in the models analyzed in subprojects 1 and 2. Through this integrated, translational approach combining basic and clinical research groups, the project aims to achieve measurable progress in defining the relevant targets and readouts for disease-modifying therapies and will set the stage for rationally designed drug trials in carefully selected groups of patients and even presymptomatic mutation carriers.'
Introduzione (Teaser)
Parkinson's disease (PD) constitutes the second most common neurodegenerative disorder. Aiming to develop novel disease-modifying and neuroprotective treatments, European neurobiologists undertook a massive study of PD's molecular basis.